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Gastric adenocarcinoma is characterised by rapid emergence of systemic metastases, resulting in poor prognosis due to vanished
curative treatment options. Better understanding of the molecular basis of gastric cancer spread is needed to design innovative
treatments. The transcription factor HIF-1a (hypoxia-inducible factor 1a) is frequently overexpressed in human gastric cancer, and
inhibition of HIF-1a has proven antitumour efficacy in rodent models, whereas the relevance of HIF-1a for the metastatic phenotype
of gastric adenocarcinoma remains elusive. Therefore, we have conducted a comprehensive analysis of the role of HIF-1a for pivotal
metastasis-associated processes of human gastric cancer. Immunhistochemistry for HIF-1a showed specific staining at the invading
tumour edge in 90% of human gastric cancer samples, whereas normal gastric tissue was negative and only a minority of early gastric
cancers (T1 tumours) showed specific staining. Hypoxia-inducible factor 1a-deficient cells showed a significant reduction of migratory,
invasive and adhesive properties in vitro. Furthermore, the HIF-1a-inhibitor 2-methoxy-estradiol significantly reduced metastatic
properties of gastric cancer cells. The accentuated expression at the invading edge together with the in vitro requirement of HIF-1a
for migration, invasion and adherence argues for a pivotal role of HIF-1a in local invasion and, ultimately, systemic tumour spread.
These results warrant the exploration of HIF-1a-inhibiting substances in clinical treatment studies of advanced gastric cancer.
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Gastric adenocarcinoma is the second leading cause of cancer-
related deaths worldwide with an annual incidence of 80–90/
100000 cases in Japan and 5–15/100000 in Europe (Parkin, 2001).
Surgical resection remains the only curative treatment option;
however, most patients emerge at advanced clinical stages and
typically show lymphatic tumour dissemination at the time of
diagnosis (Hohenberger and Gretschel, 2003). Here, surgical
resection under curative intent is no longer achievable leading to
a poor prognosis with 5-year survival rates of less than 30%.
Therefore, a better understanding of the molecular mechanisms
governing local invasion and systemic spread of gastric cancer is
needed to design and evaluate new therapeutic strategies for this
lethal disease.
Lack of oxygen (hypoxia) is a hallmark of solid tumour
formation and constitutes an independent prognostic factor in a
diverse range of malignant tumours (Harris, 2002; Vaupel et al,
2004). Hypoxia is associated with local invasion, metastatic spread,
resistance to radio- as well as chemotherapy and, ultimately, poor
patient prognosis in many human carcinomas (Vaupel et al, 2004).
The transcription factor HIF-1 (hypoxia-inducible factor 1)
constitutes the principal mediator of cellular adaptation to hypoxia
(Poellinger and Johnson, 2004). Hypoxia-inducible factor 1 is a
heterodimeric protein consisting of a ubiquitously expressed
b-subunit (also known as ARNT (aryl hydrocarbon receptor
nuclear translocator)) and a hypoxia-inducible a-subunit (Semen-
za, 2003). Hypoxia-inducible factor 1a expression has been shown
in a vast array of human carcinomas and their metastases by
means of immunohistochemistry (Zhong et al, 1999). For breast,
colorectal, invasive cervical and squamous cell oesophageal cancer
a positive correlation between tumoural HIF-1a expression and
prognosis has been shown (Birner et al, 2000; Bos et al, 2003;
Kurokawa et al, 2003; Kuwai et al, 2003).
Several immunhistochemical studies showed that HIF-1a is
overexpressed in gastrointestinal stromal tumours of the stomach
(Takahashi et al, 2003; Chen et al, 2005) and gastric adenocarci-
nomas but absent in normal gastric mucosa (Mizokami et al, 2006;
Sumiyoshi et al, 2006; Urano et al, 2006; Griffiths et al, 2007).
Although two studies have assessed HIF-1a as a prognostic marker
in gastrointestinal stromal tumours of the stomach (Takahashi
et al, 2003; Chen et al, 2005), conflicting data concerning patient
prognosis for gastric adenocarcinoma exist (Mizokami et al, 2006;
Sumiyoshi et al, 2006; Urano et al, 2006; Cabuk et al, 2007;
Griffiths et al, 2007). Inhibition of HIF-1a by means of RNA
interference or chemical compounds has proven antitumoural
activity in two murine gastric cancer models. Treatment of
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ssubcutaneous xenografts of the human gastric cancer cell line NCI-
H87 in nude mice with an HIF-1a-inhibiting compound resulted in
smaller and less vascularised tumours (Yeo et al, 2003). In
addition, when the human gastric cancer cell line TMK-1 stably
expressed a dominant negative form of HIF-1a, tumours grew
slower, showed smaller overall vessel area and hampered vessel
maturation when implanted orthotopically in nude mice (Stoeltzing
et al, 2004). However, besides the well characterised effects of HIF-1a
on angiogenesis and vessel maturation, a molecular mechanism for
the proposed inhibitory action of blocking HIF-1a on gastric cancer is
lacking and the precise relevance of HIF-1a for the causal
pathogenesis of gastric cancer is not well defined. To explore the
functional role of HIF-1a for the metastatic capacity of human
gastric cancer cells, we designed a lentiviral-mediated RNA-
interference system to knockdown HIF-1a in vitro. In a complemen-
tary pharmacological approach, we used the HIF-1a-inhibitor
2-methoxy-estradiol (2ME2) to investigate its effect on the migratory
and adhesive ability of gastric cancer cells. Our results showed that,
while HIF-1a was dispensable for cellular proliferation, functional and
pharmacological inactivation of the factor lead to a significant
reduction of migratory, invasive and adhesive features of human
gastric cancer cells in vitro. Hence, we characterised for the first time
the functional importance of HIF-1a for central cell biological
properties of metastatic human gastric cancer cells.
MATERIALS AND METHODS
Study population and tissues
A tissue microarray comprising tumours from patients (n¼52)
who underwent curative (R0) gastrectomy between 1995 and 2003
at the Division of Surgery and Surgical Oncology (Robert Ro ¨ssle
Hospital, Charite ´ Campus Buch, Berlin) was used. Written
informed consent for experimental immunohistochemistry was
obtained from all patients before analyses. The study was approved
by the Ethics Committee of the Charite ´, Berlin. Patients’ age ranged
from 34 to 85 years (mean 62.7±11.2 years), 41% were female
(n¼17) and 59% male (n¼24). Four patients were lost during
follow-up and thus censored at the time of last contact (mean
follow-up time 37.7±27.3 months). In one patient, the cause of
death was unknown and the death of another six patients was not
related to gastric cancer. Thirty-nine patients showed disease
relapse and 34 patients had died at the end of the study due to
gastric cancer. Staging and diagnosis of gastric carcinoma was
assessed according to the WHO classification (WHO Classification.
Tumours of the Digestive System, 2000) and the TNM classifica-
tion set out by the International Union against cancer (Wittekind
et al, 2003). Pre-neoplastic tissues, such as intestinal metaplasia
and dysplasia, have not been subjected to immunohistochemistry.
All gastric cancers in this study were adenocarcinomas of the
gastric body, signet ring cell carcinomas and adenocarcinomas
from the gastroesophageal junction were excluded from the
analysis. In addition, we included 40 specimens from patients
with early gastric cancers (EGCs), histologically defined as T1
tumours confined to the mucosal or submucosal layer but not
beyond. No clinicopathological data from these patients were
available for this study.
Cell culture and chemicals
The human gastric cancer cell lines AGS (CRL-1739, ATCC,
Rockville, MD, USA) and MKN28 (JCRB Cell Bank, Tokyo, Japan)
and the human embryonic kidney cell line 293T (CRL-11268,
ATCC) were grown in monolayer cultures in recommended
medium. Human umbilical vein endothelial cells were obtained
from PromoCell (Heidelberg, Germany) and cultured in
endothelial cell growth medium supplemented with Supplement
Mix and 2% fetal calf serum (PromoCell). Desferrioxamine
mesylate salt (DFO) and 2ME2 were purchased from Sigma-
Aldrich (Deisenhofen, Germany).
Immunohistochemistry and evaluation of immunostaining
Immunohistochemical detection of HIF-1a on human paraffin
sections was done as described in detail before (Pfander et al,
2005). Tissue samples were independently scored by an expert
pathologist (MV), who was blinded for clinical data. Staining
results for HIF-1a was classified by calculating the percentage of
epithelial cells showing specific immunoreactivity: negative
(0–10% positive nuclei), weak (10–30% positive nuclei), moderate
(30–60% positive nuclei), strong (460% positive nuclei). Only
samples showing moderate or strong immunoreactivity were
considered positive. Correlation of immunohistochemical results
with clinicopathological parameters was performed for an
exploratory purpose.
Plasmid construction and generation of cell lines stably
expressing siRNAs
Short hairpin RNA sequences against human HIF-1a and
scrambled (SCR) control oligonucleotides (TIB MOLBIOL, Berlin,
Germany) were published elsewhere (Sowter et al, 2003; Mizukami
et al, 2004). Oligonucleotides were inserted into BsrGI and XbaI
restriction sites of the lentiviral bicistronic vector pPR1, which
allows for coexpression of GFP (Leurs et al, 2003). Recombinant
lentiviruses were produced by transient transfection of pPR-HIF-
1a or pPR-scr with packaging vectors in 293T cells using the
calcium-phosphate method (Szulc et al, 2006). Vector titres were
determined by transducing 293T cells with serial dilutions of
concentrated lentivirus, and GFP was used to quantitate the
transduced cell fraction by flow cytometry 60h after transduction.
Gastric cancer cell lines stably expressing siRNAs were generated
by double transduction with lentiviruses at a multiplicity of
infection of 10 for 24h. Transduction efficiency of target cells was
determined by flow cytometry analysis of GFP using a FACSCa-
libur (Becton Dickinson, Heidelberg, Germany).
Western blot analysis
Nuclear protein extracts were prepared as described in detail
before (Cramer et al, 2008), then resolved by electrophoresis on an
8% sodium dodecyl sulphate-polyacrylamide gel, and transferred
onto a nitrocellulose membrane (Amersham Biosciences, Freiburg,
Germany). The blots were probed with monospecific HIF-1a
(AB1536; R&D Systems, Minneapolis, MN, USA) and YY1 (sc-281;
Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies.
Immunreactive proteins were visualised using the Western
Lightning Chemiluminescence Reagent Plus (Perkin Elmer Life
Sciences, Boston, MA, USA).
Quantitative real-time PCR analysis
For real-time PCR analysis, total cellular RNA was extracted with
Trizol reagent (Invitrogen, Rockville, MD, USA). First strand
cDNA was synthesised with an oligo (dT) primer and a SuperScript
First Strand Synthesis System (Invitrogen). For PCR reactions,
TaqMan PCR Universal Mastermix (for actin and phosphoglyce-
rate kinase) or SYBR GREEN PCR Master Mix (for HIF-1a-KD;
Applied Biosystems, Darmstadt, Germany) were used. Quantitative
real-time PCR analysis was performed as described in detail before
(Cramer et al, 2003). Knockdown frequency of HIF-1a was
determined with the following primers: HIF-1a-KD forward
50-CCGCTGGAGACACAATCATA-30, HIF-1a-KD reverse 50-CTT
CCTCAAGTTGCTGGTCA-30.
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Cell lines AGS and MKN28 were co-transfected with 100ng of
pHRE-Luc and 30ng of phRL-null (Promega, Mannheim,
Germany) using Effectene Transfection Reagent (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol. Measurement
of luciferase activity with the Dual Luciferase Reporter Assay
System (Promega) was performed as described before (Cramer
et al, 2008).
Cell proliferation assay
Cells (3 10
4) were seeded in triplicate into 24-well plates, and
18h later cells were placed under normoxic or hypoxic culture.
Cells were trypsinised and counted every 2 days using a
hemacytometer. Medium was not changed for the duration of
the experiment.
Migration and invasion assay
Cells (1 10
5) in serum-free DMEM or RPMI 1640 medium were
seeded in duplicate into uncoated Costar transwell inserts (8mm
pore size; Corning Costar Co., Bodenheim, Germany) for migra-
tion assays or Matrigel-coated transwell inserts (8mm pore size, BD
Biosciences, Heidelberg, Germany) for invasion assays and
incubated for 24h at 371Ci n5 %C O 2 atmosphere under normoxia
(20% O2) or hypoxia (1% O2). Random as well as directed
migration and invasion assays were performed and analysed as
described in detail before (Cramer et al, 2003).
Adhesion assay
For adhesion assay, human umbilical vein endothelial cells were
grown to confluence on 24-well plates. AGS cells were suspended
in the amount of 8 10
5 cellsml
 1 in serum-free medium and
Control
Gastric cancer
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Figure 1 Expression pattern of HIF-1a in human gastric cancer tissues. Paraffin sections were pretreated as described in Materials and Methods, and HIF-
1a was visualised by means of immunohistochemistry. (A) Negative control staining. (B–E) Expression of HIF-1a in established human gastric cancers,
showing that the vast majority of tumour cells were positively stained for HIF-1a over nuclei. Magnification  100 (A and B) and  200 (C–E).
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slabelled with 10mM BCECF/AM (Calbiochem, Darmstadt,
Germany) by 30-min incubation at 371C. Labelled AGS (2 10
5
per well) cells were then incubated with the human umbilical vein
endothelial cell monolayer for 30min at 371C. Cultures were
washed twice with PBS to remove non-adherent AGS cells.
Adherence was quantified by measuring fluorescence of attached
AGS cells using excitation of 485nm and emission of 535nm.
Statistical analysis
Statistical analysis was carried out using Prism 4.0 software
(GraphPad Software Inc., San Diego, CA, USA). Statistical
significance was determined by unpaired two-tailed t-test
(Po0.05). Patient data were analysed using the SPSS software
(SPSS Inc., Chicago, Il, USA). Survival was determined from the
date of surgery to the time of event (diagnosis of recurrence or
death) using the Kaplan–Meier method. Relationships between
positivity for HIF-1a and clinicopathological features were
evaluated using Spearman’s rank correlation coefficient (ordinally
scaled parameters) or Fisher’s exact probability test (dichotome
parameters). Statistical significance of differences in cumulative
survival curves was evaluated using the log-rank test.
RESULTS
Expression pattern of HIF-1a in human gastric cancer and
non-transformed gastric tissues
Immunohistochemistry with a monospecific, polyclonal HIF-1a
antibody showed no specific staining in normal gastric mucosa
(Supplementary Figure 1A). Furthermore, analysis of 40 cases of
EGC defined as all T1 gastric carcinomas that are confined to the
mucosal or submucosal layer but not beyond failed to detect HIF-
1a protein in tumour cells (Supplementary Figure 1B and C).
However, infiltrating inflammatory cells were frequently positive
for HIF-1a (not shown). In sharp contrast, 90% of analysed gastric
cancer samples showed positivity for HIF-1a specifically over the
nuclei of neoplastic epithelial cells (Figure 1B–E). Interestingly, no
difference in HIF-1a staining intensity was noted when well-
differentiated cancers were compared with poorly differentiated
ones. Hypoxia-inducible factor 1a positive neoplastic epithelial
cells did not show a preferential distribution with respect to tissue
architecture and were scattered unevenly throughout the tumour.
The staining pattern therefore did not resemble a hypoxia-induced
HIF-1a expression, but rather the HIF-1a stabilisation was
observed to result from oncogene gain of function and tumour
suppressor gene loss of function, respectively. Notably, compar-
able with the EGC samples, tumour-infiltrating inflammatory cells
steadily showed a specific nuclear HIF-1a staining (not shown).
Statistical analysis of patient data with the HIF-1a status failed to
detect a significant association of HIF-1a staining with venous
invasion, lymphatic invasion, lymph node metastasis or tumour
stage (Table 1). However, due to the small number of patients who
completed the follow-up (n¼41), this investigation can solely
describe a tendency of robust expression of HIF-1a in gastric
cancer cells. A valid statistical analysis could only be performed
with the help of larger patient cohorts.
Expression and activity of HIF-1a in gastric cancer cells
The role of HIF-1a for the malignant progression of gastric cancer
was studied in vitro by using the two human gastric cancer cell
lines AGS and MKN28. As shown by western blot analysis, in both
cell lines HIF-1a protein was strongly induced by hypoxia (1% O2)
and the hypoxia-mimicking agent DFO (Figure 2A and Supple-
mentary Figure 2A). Under ambient oxygen conditions (20%),
HIF-1a protein expression was not detectable in AGS and MKN28
cells. Next, the effect of hypoxia and DFO on mRNA expression of
two known HIF-1 target genes, phosphoglycerate kinase (PGK) and
carbonic anhydrase IX (CA IX), was determined by quantitative
real-time PCR. As expected, hypoxia and DFO significantly induced
mRNA expression of both target genes in AGS and MKN28 cells,
whereas hypoxic induction of these genes was higher than induction
by DFO (Figure 2B and Supplementary Figure 2B).
Inhibition of HIF-1a by RNA interference in gastric cancer
cells
To determine the effects of HIF-1a inactivation on gastric cancer
progression, we developed a lentivirus-based system for stably
expressing siRNA against HIF-1a. Human gastric cancer cells AGS
and MKN28 were transduced with lentiviral vectors containing the
H1 promoter-driven human HIF-1a siRNA (knockdown, ‘KD’) or
unspecific control siRNA (scrambled, ‘SCR’) (Leurs et al, 2003).
Efficiency of HIF-1a knockdown was identified by locus-specific
real-time PCR analysis and showed in AGS KD cells a mean
knockdown of 85.2±6.3% and in MKN28 KD of 97.2±2.1%.
Furthermore, western blot analysis showed a near complete failure
of AGS KD and MKN28 KD cells to induce HIF-1a protein under
hypoxic conditions (Figure 2C and Supplementary Figure 2C). To
further characterise the functional inhibition of HIF-1a,w e
determined mRNA expression of the HIF-1 target genes PGK
and CA IX as outlined above. As shown in Figure 2E, hypoxia
induced the expression of these genes in both control cell lines,
whereas hypoxic induction of these genes in AGS KD and MKN28
KD cells was markedly reduced (Supplementary Figure 2E). To
confirm that not only HIF-1a protein and HIF-1 target gene
expression but also HIF-1a activity was reduced in KD cells, an
HRE-luciferase reporter assay was performed. Hypoxic stimulation
resulted in a significant decrease of HRE-luc reporter activity in
AGS KD and MKN28 KD cells compared with their respective
control cells (Figure 2D and Supplementary Figure 2D). Taken
together, these results show that our lentivirus-based siRNA
system lead to a strong and stable inactivation of HIF-1a in a
different panel of human gastric cancer cell lines.
Effects of HIF-1a inhibition on proliferation of gastric
cancer cells in vitro
Given the widespread acceptance of HIF-1a as a positive regulator
of cellular proliferation (Dang et al, 2006), we characterised the
Table 1 Relationship between HIF-1a protein expression in tumour
tissues from tissue microarrays and clinicopathological parameters
No. HIF-1a (%) P-value
Venous invasion
Absent 29 (71%) 95.00 0.065
Present 12 (29%) 99.58
Lymphatic invasion
Absent 24 (59%) 96.88 0.582
Present 17 (41%) 95.59
Lymph node metastases (pN0-3)
N0 11 (27%) 95.91 0.820
N1 20 (49%) 95.75
N2 6 (15%) 98.33
N3 4 (10%) 97.50
Tumour infiltration (pT)
T1 7 (17%) 98.57 0.378
T2 20 (49%) 95.75
T3 11 (27%) 95.00
T4 3 (7%) 100.00
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can be seen in Figure 3, loss of HIF-1a did not interfere with
proliferation of AGS and MKN28 cells under anchorage-dependent
conditions neither in normoxic nor hypoxic conditions. However,
during hypoxic culture, gastric cancer cells were not able to sustain
exponential growth, and both KD and control cells had significant
decreases in cell numbers compared with cell growth under
ambient oxygen conditions (Figure 3A and B; right panels). These
results suggest that HIF-1a is not essential for cell proliferation of
these two gastric cancer cell lines under adherent conditions.
Inhibition of the metastatic cascade in vitro through
functional inactivation of HIF-1a
Next, we determined the impact of HIF-1a inactivation on
functional aspects of malignant cell behaviour, including migra-
tion, invasion and interaction with endothelial cells. To determine
if HIF-1a is involved in gastric cancer cell motility, we compared
the migratory and invasive capacity of HIF-1a KD and control
cells. Directed migration of AGS cells was significantly reduced by
the loss of HIF-1a under both normoxic and hypoxic conditions to
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Figure 2 Expression and inhibition of HIF-1a in the human gastric cancer cell line AGS. Cells were cultured under normoxia (N) or hypoxia (H) or
treated with 100 mM DFO. (A) HIF-1a protein levels were analysed in nuclear extracts by western blot analysis, with YY1 serving as nuclear loading control.
Induction of HIF-1a protein was quantified by densitometry. Hypoxia-inducible factor 1 protein was found to be expressed in AGS cells under both hypoxia
and DFO treatment. (B) Transcription of the HIF-1 target genes 3-phosphoglycerate kinase (PGK) and carbonic anhydrase IX (CA IX) was analysed by
quantitative real-time PCR. Hypoxic culture and treatment with DFO resulted in induction of PGK (**Pp0.0086) and CA IX (**Pp0.0060) mRNAs. Values
were normalised to that of b-actin, and relative expression was compared with the same cell line in hypoxia or DFO treatment vs normoxia. Values are
means±s.e.m. (C) Western blot analysis of nuclear extracts from knockdown (KD) and control (SCR) AGS cells under normoxia (N) or hypoxia (H) for
16h. AGS KD cells were unable to express HIF-1a protein under hypoxic culture. Differences in hypoxia-induced nuclear HIF-1a protein levels were
quantified by densitometry. (D) Confirmation of loss of HIF-1a function by HRE-luc reporter assay. AGS KD and SCR cells were co-transfected with an
HRE-luc reporter and phRL-null Renilla as an internal control and incubated under either normoxia or hypoxia for 24h. Inhibition of HIF-1a resulted in a
significant decrease of HRE-luc reporter activity under hypoxic conditions (***Po0.0001). Luciferase activity, normalised to Renilla luciferase activity, was
expressed relative to that of transfected control cells (SCR) under normoxia, set at 1.0. Results shown are representative of three independent experiments,
and values represent the mean±s.e.m. of triplicate determinations. (E) Expression of HIF-1 target genes PGK and CA IX was measured relative to b-actin by
quantitative real-time PCR. Inhibition of HIF-1a protein by RNAi resulted in decreased transcription of HIF-1 target genes PGK (*P¼0.0125) and CA IX
(*P¼0.0421) in AGS KD cells. Transcription levels were expressed relative to that of control cells (SCR) under normoxia, set at 1.0. Values represent the
means±s.e.m.
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s30 and 24%, respectively (Figure 4A). Similarly, inactivation of
HIF-1a in MKN28 cells reduced directed migration to 70% under
both normoxic and hypoxic conditions (Figure 4B). In good
agreement with our observations on migration, loss of HIF-1a in
AGS cells reduced directed invasion to 70% under normoxia and to
55% under hypoxic conditions when compared with control cells
under normoxia (Figure 4C). Generally, directed migration and
invasion of AGS cells was decreased under hypoxic conditions
when compared with normoxia (Figure 4A and C).
Inhibition of HIF-1a reduces adhesion to the endothelium
in vitro
Lymphatic and blood vessels are the major pathways for cancer
cell dissemination. Interactions between circulating intravascular
cancer cells and endothelial cells have a significant influence on the
fate of metastatic cells and on the outcome of the metastatic
process. To evaluate the direct impact of HIF-1a on interaction
between malignant cells and the endothelium, cell adhesion assays
were performed. As shown in Figure 4D, inhibition of HIF-1a
significantly reduced adhesion of AGS cells to endothelial cell
monolayers to 81% under normoxia and to 57% in hypoxic culture
compared with relative adhesion of control cells under normoxia.
Furthermore, the adhesion of both AGS KD and AGS SCR cells was
lower under hypoxic conditions than under normoxia (Figure 4D).
2ME2 inhibits HIF-1a and reduces the metastatic capacity
of gastric cancer cells
2-methoxy-estradiol, a naturally occurring metabolite of estradiol,
is an orally active small molecule with antitumour and antiangiogenic
activity currently in phase I/II clinical trials (Schumacher and
Neuhaus, 2006). It has been shown that 2ME2 downregulates HIF-1
protein at the posttranscriptional level and inhibits its transcrip-
tional activity (Mabjeesh et al, 2003). We first examined the effects
of 2ME2 treatment on HIF-1a protein in the gastric cancer cell line
AGS. As shown in Figure 5A, exposure of AGS cells to 2ME2
reduced the levels of nuclear HIF-1a protein under hypoxia in a
dose-dependent manner. To further investigate the effects of 2ME2
treatment on HIF-1 transcriptional activity, we performed an HRE-
luciferase reporter assay as described before. Consistent with the
reduced levels of HIF-1a nuclear protein, treatment with 2ME2
resulted in a significant and dose-dependent decrease of hypoxia-
induced transcriptional activity of HIF-1a (Figure 5B). Owing to
the antimetastatic acitivity of 2ME2, we investigated whether
treatment with 2ME2 attenuates metastatic properties of the gastric
cancer cell line AGS. Therefore, AGS cells were pretreated with
increasing concentrations of 2ME2 for 24h and migration,
invasion and adhesion assays were performed. As shown in
Figure 5C, reduced cell migration was observed in AGS cells
treated with 5 mM 2ME2 but a more significant reduction was
found after treating the cells with 10 and 20mM 2ME2 compared
with the control. Similarly, treatment of AGS cells with 10mM 2ME2
led to a significant suppression of directed invasion to 17%
compared with invasion of vehicle-treated cells (Figure 5D).
Finally, inhibition of HIF-1a by means of 2ME2 significantly
reduced adhesion of AGS cells to endothelial cell monolayers to
59% compared with relative adhesion of vehicle-treated cells
(Figure 5E).
DISCUSSION
Here, we describe for the first time that HIF-1a constitutes a
central metastasis-supporting factor in human gastric adenocarci-
noma. We provide experimental evidence for reduced metastatic
properties of gastric cancer cells through functional inactivation of
HIF-1a, even under conditions of ambient oxygen. Our character-
isation of the temporospatial expression patterns of HIF-1a protein
during the pathogenesis of human gastric adenocarcinoma are in
line with earlier studies showing HIF-1a protein expression in the
majority of human gastric cancer samples (Urano et al, 2006;
Cabuk et al, 2007; Griffiths et al, 2007). In contrast, two Japanese
studies reported lower percentages of HIF-1a-positive tumour cells
in human gastric adenocarcinoma samples (Mizokami et al, 2006;
Sumiyoshi et al, 2006). Absolute patient numbers and tissue types
were comparable in these studies, ruling out an impact on HIF-1a
distribution. However, significant differences in staining proce-
dures and scoring protocols were noted and constitute the most
likely explanation for the reported differences in the relative
number of HIF-1a-positive tumour cells. Our analysis of EGC
samples detected specific nuclear expression of HIF-1a in only
15% of the examined cases. Although this result is in line with one
previous study showing specific HIF-1a staining in 29% of T1
tumours (Sumiyoshi et al, 2006), two other articles reported
strikingly different results (HIF-1a positivity in 68 and 100% of T1
tumours) (Urano et al, 2006; Cabuk et al, 2007). Given these sharp
contrasts, a definite agreement on the expression pattern of HIF-1a
in T1 gastric adenocarcinomas cannot be reached at this point and
should be clarified by future work. We noted robust nuclear
expression of HIF-1a at the invading tumour edge, confirming
previously published results (Sumiyoshi et al, 2006). Hence,
tissue-infiltrating gastric tumour cells seemed particularly reliant
on HIF-1a. These results lead us to speculate that the role of
HIF-1a in the pathogenesis of human gastric cancer might be most
pronounced in advanced stages of the disease. Therefore, we
performed an array of in vitro experiments aimed at defining the
importance of HIF-1a for local invasion and metastatic spread of
gastric cancer cells.
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Figure 3 Effects of HIF-1a inhibition on growth of AGS and MKN28 cells
in vitro. Anchorage-dependent proliferation of AGS (A) and MKN28 (B)
knockdown (KD) and control (SCR) cells under normoxia (left panels) or
hypoxia (right panels). Cells were counted every other day from day 2 to 6
using a hemacytometer. Gastric cancer KD cells grew at approximately the
same rate as SCR cells under both normoxia and hypoxia. Results shown
are representative of three independent experiments and values represent
the mean±s.e.m. of duplicate determinations.
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expression by hypoxia and the hypoxia-mimicking agent DFO,
whereas normoxic expression of HIF-1a could not be observed in
AGS and MKN28 cells. Hypoxic induction of HIF-1a in AGS cells
has been described by others before and is confirmed by our data
(Huang et al, 2005; Cai et al, 2006). However, MKN28 cells have
not been analysed for the expression profile of HIF-1a thus far.
Induction of HIF-1a protein and target gene expression by culture
under hypoxic conditions has been described for a wide variety of
human cancer cell lines, for example, colon, pancreas, breast and
prostate cancer (Zhong et al, 1998; Ravi et al, 2000; Akakura et al,
2001; Tacchini et al, 2004). Two basic expression patterns of HIF-
1a in cancer cell lines are known: inducible and constitutive
expression (Akakura et al, 2001). The latter being explained by the
observation that loss of tumour-suppressor genes, for example,
vhl, or activation of oncogenes such as ras or src can directly
activate HIF-1a (Jiang et al, 1997; Maxwell et al, 1999; Blancher
et al, 2001). Our results show that in both gastric cancer cell lines
investigated, HIF-1a protein is not detectable under normoxic
conditions by means of western blot. However, despite the lack of
detectable protein expression, HIF-1a can still be functional under
normoxic conditions. This has been observed by us and others
before and is most likely explained by technical detection
limitations due to the extremely short half-life of HIF-1a under
normoxic conditions (Semenza, 2002; Cramer et al, 2003).
Proliferation of AGS and MKN28 cells showed similar results for
HIF-1a-deficient and control cells. Interestingly, this result was
noted both for normoxic and hypoxic culture conditions, arguing
for a neglectable role of HIF-1a for both normoxic and hypoxic
proliferation of these cell types. These results stand in contrast to
the analysis of immortalised murine embryonic fibroblasts, where
a genetic inactivation of HIF-1a resulted in a substantial growth
defect under hypoxia (Seagroves et al, 2001). Furthermore, murine
mammary tumour cells from mice with Cre-loxP-mediated
inactivation of HIF-1a failed to reach the logarithmic growth
phase under low oxygen conditions (Liao et al, 2007). In line with
these observations, human colon cancer cell lines HCT116 and
RKO showed a growth defect under both normoxic and hypoxic
conditions when HIF-1a was inactivated (Dang et al, 2006). Hence,
our analysis for the first time describes a HIF-1a-independent
proliferation pattern of malignant cells with respect to oxygen
concentration. Therefore, HIF-1a seems negligible for the growth
of AGS and MKN28 cells under anchorage-dependent conditions.
As outlined above, most patients present with advanced disease
due to either local invasion of neighbouring organs or the
occurrence of distant metastases. Once the primary tumour has
spread systemically, no curative treatment options remain and the
treatment goal is purely palliative. Therefore, continued research
efforts to better understand the molecular mechanisms of systemic
tumour spread are urgently needed. The classical metastatic
cascade encompasses entry of blood vessels by tumour cells, their
survival in the vascular network, arrest in distant organs,
extravasation and ultimately growth into metastatic foci
(Bogenrieder and Herlyn, 2003; Steeg, 2006). Our functional
analysis of the role of HIF-1a in the pathogenesis of human
gastric cancer comprised central characteristics of metastatic cells,
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Figure 4 Effects of HIF-1a inactivation on migration, invasion and adhesion of AGS and MKN28 cells. Migration of AGS (A) and MKN28 (B) knockdown
(KD) and control (SCR) cells was evaluated in 24-well Transwell chambers (8mm pore size) under normoxia or hypoxia for 24h. Directed migration of KD
cells was significantly impaired compared with SCR cells under both normoxia and hypoxia (**Pp0.0056; *Pp0.0281). The number of migrated cells on the
bottom side of the filter was determined and normalised to the number of migrated SCR cells under normoxic conditions. Data represent mean±s.e.m. of a
representative out of three experiments, each performed in duplicate. Photos show the bottom of representative migration filters. (C) For invasion assay,
AGS KD and SCR cells were seeded into Matrigel-coated transwell inserts (8mm pore size) and incubated under normoxia or hypoxia for 24h. Hypoxia
decreased the invasion of both AGS KD and SCR cells. Inactivation of HIF-1a reduced directed invasion of AGS cells significantly under normoxia and
hypoxia (*Pp0.0266; **P¼0.0048). The number of invading cells was normalised to the number of invading SCR cells under normoxic conditions. Bars
show means±s.e.m. of a representative experiment out of two experiments, each performed in duplicate. Photos show the bottom of representative
invasion filters. (D) For adhesion assay, BCECF/AM labelled AGS KD and SCR cells were added to an HUVEC monolayer and allowed to adhere for 30min
under normoxia or hypoxia. Adhesion of AGS cells to HUVEC endothelial cells was reduced under normoxic and hypoxic conditions by loss of HIF-1a
(*P¼0.0327; **Pp0.0025). Adhesion was expressed relative to that of control cells (SCR) under normoxic conditions. Shown are mean±s.e.m. of three
independent experiments, each performed in triplicate.
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(Steeg, 2006). Functional inactivation of HIF-1a resulted in a
significantly reduced ability of AGS and MKN28 gastric cancer
cells to migrate and to invade an artificial basal membrane under
normoxic as well as hypoxic conditions. Furthermore, HIF-1a-
competent cells showed a significantly better adherence to
endothelial cells without reference to the oxygen concentration.
Reduced migratory capacitiy of HIF-1a-deficient cells has been
shown for a wide variety of primary and transformed cells, for
example, neutrophils, macrophages, glioma and small cell lung
cancer cells (Cramer et al, 2003; Liu et al, 2006; Zagzag et al, 2006).
In the case of primary murine phagocytes, a highly reduced
content of intracellular ATP has been shown to be the underlying
molecular mechanism, most likely due to the pivotal role of HIF-1a
for glycolysis (Seagroves et al, 2001; Cramer et al, 2003). However,
in our experiments we could neither show lowered ATP levels in
HIF-1a-deficient gastric cancer cells nor did addition of excess free
ATP rescue the motility of HIF-1a-deficient cells (data not shown).
Various research groups have reported a permissive role of HIF-1a
for the invasive capacity of transformed and non-transformed cell
types (Cramer et al, 2003; Miyoshi et al, 2006; Zagzag et al, 2006).
Here, HIF-1a-controlled expression of matrix metalloproteinase 2,
cathepsin D and urokinase plasminogen activator receptor have
been implicated among others as key molecular players (Semenza,
2003). The precise mechanism(s) of the reduced invasive capacity
of AGS and MKN28 gastric cancer cells without functional HIF-1a
has not been determined here and remains a topic for future
research.
Research on the oncogenic role of HIF-1a has gained significant
attention in recent years. Hypoxia-inducible factor 1a expression is
associated with limited survival and poor treatment outcome in
breast, brain, colon and lung cancer. Functional inhibition of HIF-
1a by means of dominant negative expression constructs or stable
siRNA transfection led to significant reduction of neoplastic
growth in a broad array of rodent tumour models. 2-methoxy-
estradiol has been shown by independent international research
groups to potently inhibit HIF-1a in vitro and in vivo. These
preclinical studies led to the realisation of clinical phase I and II
trials aimed at testing the safety and efficacy of 2ME2 as a novel
anticancer drug. Our results show a potent inhibiting effect of
2ME2 on protein expression and activity of HIF-1a in gastric
cancer cells. These results are well in line with other studies
showing an anti-HIF-1a effect of 2ME2, for example, on breast,
colon and pancreatic cancer cells. Furthermore, we were able to
characterise a substantial inhibiting effect of 2ME2 on the
migratory, invasive and adhesive properties of gastric cancer cells.
These results confirm our experiments with the RNAi-mediated
HIF-1a inhibition and therefore firmly establish a functional role
of HIF-1a for migration and invasion of gastric cancer cells.
Against this background and given the widespread expression of
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Figure 5 Effects of 2ME2 on HIF-1a protein and transcriptional activity and on metastatic properties of AGS cells. (A) AGS cells were treated for 24h
with vehicle or increasing concentrations of 2ME2, and inhibition of HIF-1a was analysed by western blot analysis. Treatment with 2ME2 led to a dose-
dependent reduction of HIF-1a protein. (B) HRE-luc reporter assay. AGS cells transfected with an HRE-luc reporter, and phRL-null Renilla were treated with
vehicle or increasing concentrations of 2ME2 under either normoxia or hypoxia for 24h. Exposure to 2ME2 resulted in a significant decrease of HRE-luc
reporter activity under hypoxic conditions (***P¼0.0004; **Pp0.0089). Luciferase activity, normalised to Renilla luciferase activity, was expressed relative
to that of transfected control cells under normoxia, set at 1.0. Results shown are representative of three independent experiments, and values represent the
mean±s.e.m. of triplicate determinations. (C) Migration of AGS cells was evaluated in 24-well transwell chambers (8mm pore size) after treatment with
either vehicle or increasing concentrations of 2ME2 under normoxia for 24h. Directed migration of 2ME2-treated cells was significantly impaired compared
with vehicle-treated cells (*P¼0.0246; **P¼0.002; ***P¼0.001). The number of migrated cells on the bottom side of the filter was determined and
normalised to the number of vehicle-treated cells. Results shown are representative of three independent experiments, and values represent the
mean±s.e.m. of duplicate determinations. Photos show the bottom of representative migration filters. (D) For invasion assay, AGS cells were seeded into
Matrigel-coated transwell inserts (8mm pore size) after pretreatment with either vehicle or 10mM 2ME2 for 24h. Invasion of 2ME2-treated cells was
significantly reduced compared with vehicle-treated cells (***Po0.0001). Bars show means±s.e.m. of a representative experiment out of two experiments,
each performed in duplicate. Photos show the bottom of representative invasion filters. (E) For adhesion assay, AGS cells were pretreated with either
vehicle or 10mM 2ME2 for 24h, labelled with BCECF/AM and allowed to adhere to HUVEC endothelial cells for 30min. Treatment with 2ME2 significantly
reduced adhesion of AGS cells to an HUVEC monolayer (***P¼0.0002). Shown are means±s.e.m. of two independent experiments, each performed in
triplicate.
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include 2ME2 (or other equally effective HIF-1a-inhibiting agents)
in study protocols against gastric cancer.
Taken together, we performed a detailed analysis of the role of
HIF-1a for human gastric cancer in vitro and in vivo. Hypoxia-
inducible factor 1a was expressed in about 90% of late gastric
cancer samples, whereas the factor could not be identified in EGCs.
Functional inhibition of HIF-1a by means of lentiviral-mediated
siRNA delivery resulted in suppression of a diverse range of
metastasis-associated pathways in vitro. Hence, our data argue for a
pivotal role of HIF-1a in the pathogenesis of later stages of human
gastric cancer and its systemic spread. These results warrant the
design and execution of clinical studies to test the efficacy of
inhibitors of HIF-1a in the treatment of patients with gastric cancer.
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